m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01407)
Name
NSC-345763
Synonyms
NSC-345763; 7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114
    Click to Show/Hide
Status
Investigative
Structure
Formula
C16H15NO5
InChI
1S/C16H15NO5/c18-10(4-8-15(21)22)3-6-13(19)11-5-7-14(20)16-12(11)2-1-9-17-16/h1-2,5,7,9,20H,3-4,6,8H2,(H,21,22)
InChIKey
SDIIGLWXEVMFDA-UHFFFAOYSA-N
PubChem CID
335596
TTD Drug ID
D0MP7N
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-345763. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-345763 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). [1], [2]
References
Ref 1 m6A hypomethylation of DNMT3B regulated by ALKBH5 promotes intervertebral disc degeneration via E4F1 deficiency. Clin Transl Med. 2022 Mar;12(3):e765. doi: 10.1002/ctm2.765.
Ref 2 Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. doi: 10.1016/j.bmc.2009.11.050. Epub 2009 Nov 27.